SAGIMET BIOSCIENCES INC.

Analyst Reco. Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
5.17 ^USD	+7.26%		+7.26%	-4.61%

May. 16	Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating	MT
May. 15	Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating	May. 16	MT
HC Wainwright Starts Sagimet Biosciences With Buy Rating, $32 Price Target	May. 02	MT
Goldman Sachs Adjusts Sagimet Biosciences' Price Target to $27 From $37, Maintains Buy Rating	Mar. 26	MT
Leerink Partners Initiates Sagimet Biosciences With Outperform Rating, $26 Price Target	Mar. 25	MT
JMP Securities Adjusts Price Target on Sagimet Biosciences to $46 From $47, Maintains Market Outperform Rating	Feb. 07	MT
Goldman Sachs Raises Price Target on Sagimet Biosciences to $37 From $30, Keeps Buy Rating	Jan. 23	MT
JMP Securities Raises Price Target on Sagimet Biosciences to $47 From $31, Maintains Market Outperform Rating	Jan. 23	MT
TD Cowen Initiates Sagimet Biosciences With Outperform Rating	23-08-08	MT
Goldman Sachs Initiates Sagimet Biosciences at Buy With $33 Price Target	23-08-08	MT
Piper Sandler Initiates Sagimet Biosciences With Overweight Rating, $67 Price Target	23-08-08	MT
JMP Securities Starts Sagimet Biosciences With Market Outperform Rating, $30 Price Target	23-08-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer